
Chemotherapy Induced Peripheral Neuropathy Treatment Industry Research Report 2025
Description
Summary
According to APO Research, The global Chemotherapy Induced Peripheral Neuropathy Treatment market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Chemotherapy Induced Peripheral Neuropathy Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Chemotherapy Induced Peripheral Neuropathy Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Chemotherapy Induced Peripheral Neuropathy Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Chemotherapy Induced Peripheral Neuropathy Treatment include Apexian Pharma, Aptinyx Inc, Asahi Kasei Pharma Corp, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, MAKScientific LLC, Metys Pharmaceuticals AG and Nemus Bioscience Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chemotherapy Induced Peripheral Neuropathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy Induced Peripheral Neuropathy Treatment.
The Chemotherapy Induced Peripheral Neuropathy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chemotherapy Induced Peripheral Neuropathy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Company
Apexian Pharma
Aptinyx Inc
Asahi Kasei Pharma Corp
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PeriphaGen
PledPharma
Regenacy Pharmaceuticals
Sova Pharmaceuticals Inc
WinSanTor
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
Antidepressants
Calcium Channel α2-delta Ligands
Opioids
Others
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
Platinum Agents
Vinca Alkaloids
Taxanes
Others
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
Platinum Agents
Vinca Alkaloids
Taxanes
Others
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Peripheral Neuropathy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Peripheral Neuropathy Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Chemotherapy Induced Peripheral Neuropathy Treatment market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Chemotherapy Induced Peripheral Neuropathy Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Chemotherapy Induced Peripheral Neuropathy Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Chemotherapy Induced Peripheral Neuropathy Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Chemotherapy Induced Peripheral Neuropathy Treatment include Apexian Pharma, Aptinyx Inc, Asahi Kasei Pharma Corp, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, MAKScientific LLC, Metys Pharmaceuticals AG and Nemus Bioscience Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chemotherapy Induced Peripheral Neuropathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy Induced Peripheral Neuropathy Treatment.
The Chemotherapy Induced Peripheral Neuropathy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chemotherapy Induced Peripheral Neuropathy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Company
Apexian Pharma
Aptinyx Inc
Asahi Kasei Pharma Corp
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PeriphaGen
PledPharma
Regenacy Pharmaceuticals
Sova Pharmaceuticals Inc
WinSanTor
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
Antidepressants
Calcium Channel α2-delta Ligands
Opioids
Others
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
Platinum Agents
Vinca Alkaloids
Taxanes
Others
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
Platinum Agents
Vinca Alkaloids
Taxanes
Others
Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Peripheral Neuropathy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Peripheral Neuropathy Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
123 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Chemotherapy Induced Peripheral Neuropathy Treatment by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 Antidepressants
- 2.2.3 Calcium Channel α2-delta Ligands
- 2.2.4 Opioids
- 2.2.5 Others
- 2.3 Chemotherapy Induced Peripheral Neuropathy Treatment by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Platinum Agents
- 2.3.3 Vinca Alkaloids
- 2.3.4 Taxanes
- 2.3.5 Others
- 2.4 Assumptions and Limitations
- 3 Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by Type
- 3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Type (2020-2025)
- 3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Type (2026-2031)
- 4 Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by Application
- 4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Application (2020-2025)
- 4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Perspective (2020-2031)
- 5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Growth Trends by Region
- 5.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Region (2020-2025)
- 5.2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Region (2026-2031)
- 5.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics
- 5.3.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
- 5.3.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
- 5.3.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
- 5.3.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Revenue
- 6.1.1 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Revenue (2020-2025)
- 6.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Players (2020-2025)
- 6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Chemotherapy Induced Peripheral Neuropathy Treatment Head Office and Area Served
- 6.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Players, Product Type & Application
- 6.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Established Date
- 6.6 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2020-2031)
- 7.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2020-2025)
- 7.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2020-2031)
- 8.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2020-2025)
- 8.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2020-2031)
- 9.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2020-2031)
- 10.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2020-2025)
- 10.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2020-2031)
- 11.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Apexian Pharma
- 12.1.1 Apexian Pharma Company Information
- 12.1.2 Apexian Pharma Business Overview
- 12.1.3 Apexian Pharma Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.1.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.1.5 Apexian Pharma Recent Developments
- 12.2 Aptinyx Inc
- 12.2.1 Aptinyx Inc Company Information
- 12.2.2 Aptinyx Inc Business Overview
- 12.2.3 Aptinyx Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.2.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.2.5 Aptinyx Inc Recent Developments
- 12.3 Asahi Kasei Pharma Corp
- 12.3.1 Asahi Kasei Pharma Corp Company Information
- 12.3.2 Asahi Kasei Pharma Corp Business Overview
- 12.3.3 Asahi Kasei Pharma Corp Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.3.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.3.5 Asahi Kasei Pharma Corp Recent Developments
- 12.4 DermaXon LLC
- 12.4.1 DermaXon LLC Company Information
- 12.4.2 DermaXon LLC Business Overview
- 12.4.3 DermaXon LLC Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.4.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.4.5 DermaXon LLC Recent Developments
- 12.5 Kineta Inc
- 12.5.1 Kineta Inc Company Information
- 12.5.2 Kineta Inc Business Overview
- 12.5.3 Kineta Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.5.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.5.5 Kineta Inc Recent Developments
- 12.6 Krenitsky Pharmaceuticals Inc
- 12.6.1 Krenitsky Pharmaceuticals Inc Company Information
- 12.6.2 Krenitsky Pharmaceuticals Inc Business Overview
- 12.6.3 Krenitsky Pharmaceuticals Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.6.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.6.5 Krenitsky Pharmaceuticals Inc Recent Developments
- 12.7 MAKScientific LLC
- 12.7.1 MAKScientific LLC Company Information
- 12.7.2 MAKScientific LLC Business Overview
- 12.7.3 MAKScientific LLC Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.7.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.7.5 MAKScientific LLC Recent Developments
- 12.8 Metys Pharmaceuticals AG
- 12.8.1 Metys Pharmaceuticals AG Company Information
- 12.8.2 Metys Pharmaceuticals AG Business Overview
- 12.8.3 Metys Pharmaceuticals AG Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.8.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.8.5 Metys Pharmaceuticals AG Recent Developments
- 12.9 Nemus Bioscience Inc
- 12.9.1 Nemus Bioscience Inc Company Information
- 12.9.2 Nemus Bioscience Inc Business Overview
- 12.9.3 Nemus Bioscience Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.9.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.9.5 Nemus Bioscience Inc Recent Developments
- 12.10 PeriphaGen
- 12.10.1 PeriphaGen Company Information
- 12.10.2 PeriphaGen Business Overview
- 12.10.3 PeriphaGen Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.10.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.10.5 PeriphaGen Recent Developments
- 12.11 PledPharma
- 12.11.1 PledPharma Company Information
- 12.11.2 PledPharma Business Overview
- 12.11.3 PledPharma Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.11.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.11.5 PledPharma Recent Developments
- 12.12 Regenacy Pharmaceuticals
- 12.12.1 Regenacy Pharmaceuticals Company Information
- 12.12.2 Regenacy Pharmaceuticals Business Overview
- 12.12.3 Regenacy Pharmaceuticals Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.12.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.12.5 Regenacy Pharmaceuticals Recent Developments
- 12.13 Sova Pharmaceuticals Inc
- 12.13.1 Sova Pharmaceuticals Inc Company Information
- 12.13.2 Sova Pharmaceuticals Inc Business Overview
- 12.13.3 Sova Pharmaceuticals Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.13.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.13.5 Sova Pharmaceuticals Inc Recent Developments
- 12.14 WinSanTor
- 12.14.1 WinSanTor Company Information
- 12.14.2 WinSanTor Business Overview
- 12.14.3 WinSanTor Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2020-2025)
- 12.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 12.14.5 WinSanTor Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.